## AMENDMENTS TO THE CLAIMS

1-32. (canceled)

33. (currently amended) A method for modulating the activity of a kinase involved in signal transduction in a subject in need thereof comprising irradiating said subject with light after administration of a compound of the formula




1 2




3 4

. or their 1,4-diene isomers

or the metallated and/or labeled and/or conjugated forms thereof

wherein each $R^1$ is independently alkyl (1-6C);

each n is independently an integer of 0-6; and

$R^2$ is vinyl or a derivative thereof,

thereby modulating the activity of said kinase involved in signal transduction.

34. (previously presented) The method of claim 33 wherein in said compound, $R^2$ is vinyl, -CHOR', -CHO, -COOR', $-CH(OR')CH_3$, $-CH(OR')CH_2OR'$, $-CH(SR')CH_3$, $-CH(NR')_2CH_3$, $-CH(CN)CH_3$, $-CH(COOR')CH_3$, $-CH(OOCR')CH_3$, $-CH(NR'COR')CH_3$, $-CH(CONR'_2)CH_3$, $-CH(halo)CH_3$, or $-CH(halo)CH_2(halo)$ wherein R' is H, or a hydrocarbon radical (1-6C) optionally substituted with a heteroatom substituent.

35. (previously presented) The method of claim 33 wherein in said compound, $R^2$ is an organic group of less than 12C resulting from derivatization of a vinyl substituent.

36. (previously presented) The method of claim 33 wherein in said compound, $R^2$ is a group containing 1-3 tetrapyrrole nuclei.

37. (previously presented) The method of claim 33 wherein said compound is in a metallated form.

38. (previously presented) The method of claim 33 wherein said compound is in conjugated form.

39. (previously presented) The method of claim 33 wherein said compound is labeled.

40. (previously presented) The method of claim 33 wherein said compound does not contain a metal ion.

41. (previously presented) The method of claim 33 wherein in said compound, $R^2$ is vinyl.

42. (previously presented) The method of claim 33 wherein in said compound, each $R^1$ is methyl.

43. (previously presented) The method of claim 33 wherein in said compound, both n are 2.

44. (previously presented) The method of claim 43 wherein in said compound, $R^2$ is vinyl and both $R^1$ are methyl.

45. (previously presented) The method of claim 33 wherein said compound is of formulas 1-4.

46. (previously presented) The method of claim 45 wherein in said compound, $R^2$ is vinyl, -CHOR', -CHO, -COOR', $-CH(OR')CH_3$, $-CH(OR')CH_2OR'$, $-CH(SR')CH_3$, $-CH(NR')_2CH_3$, $-CH(CN)CH_3$, $-CH(COOR')CH_3$, $-CH(OOCR')CH_3$, $-CH(NR'COR')CH_3$, $-CH(CONR'_2)CH_3$, $-CH(halo)CH_3$, or $-CH(halo)CH_2(halo)$ wherein R' is H, or a hydrocarbon radical (1-6C) optionally substituted with a heteroatom substituent.

47. (previously presented) The method of claim 45 wherein in said compound, $R^2$ is an organic group of less than 12C resulting from derivatization of a vinyl substituent.

48. (previously presented) The method of claim 45 wherein in said compound, $R^2$ is vinyl.

49. (previously presented) The method of claim 45 wherein in said compound, each $R^1$ is methyl.

50. (previously presented) The method of claim 45 wherein in said compound, both n are 2.

51. (previously presented) The method of claim 50 wherein in said compound, $R^2$ is vinyl and both $R^1$ are methyl.

52. (previously presented) The method of claim 44 wherein said compound is A-EA6 or B-EA6 or the metallated and/or labeled and/or conjugated forms thereof.

53. (previously presented) The method of claim 52 wherein said compound is in a metallated form.

54. (previously presented) The method of claim 52 wherein said compound is in conjugated form.

55. (previously presented) The method of claim 52 wherein said compound is labeled.

56. (previously presented) The method of claim 52 wherein said compound does not contain a metal ion.

57. (previously presented) The method of claim 33 wherein said kinase is a mitogenic pathway kinase or a stress pathway kinase.

58. (previously presented) The method of claim 57, wherein said kinase is p70 S6K, c-jun or HSP27.